Hydrocortisone may act through the angiotensin II receptor-2 level in patients with catecholamine-resistant septic shock
| Autor: | Seyma, Baykan, Murat, Bicakcioglu, Nilüfer, Bulut, Neslihan, Yucel, Yasemin, Ersoy, Nermin, Kibrislioglu Uysal, Ayse B, Ozer |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Minerva Anestesiologica. 89 |
| ISSN: | 1827-1596 0375-9393 |
| DOI: | 10.23736/s0375-9393.22.16766-0 |
| Popis: | This study aimed to compare the serum angiotensin II and its receptor levels (AT1, AT2) in septic patients with catecholamine-responsive or resistant. The effect of hydrocortisone treatment on angiotensin II levels in the catecholamine-resistant septic patients was evaluated.This prospective observational study enrolled 40 patients diagnosed with septic shock based on sepsis-3 criteria. Patients were divided into two groups according to the noradrenalin infusion rate required to keep the mean arterial pressure above 65 mmHg: Control Group and Hydrocortisone Group (control group: below 0.5μg/kg/min, hydrocortisone group: above 0.5μg/kg/min). Serum angiotensin II, AT1, AT2 levels were measured at the time of diagnosis (A), one hour after hydrocortisone treatment (B), and three days later (C).In the catecholamine-resistant group, angiotensin II and AT1 levels were higher than the catecholamine-responder group in all periods. The sensitivity and specificity of AT-1 was observed to be high in all periods. AT2 levels decreased after hydrocortisone treatment in the catecholamine-resistant group and cut-off value was found 11%.It was concluded that angiotensin II and AT1 can be used as a biomarker of refractory septic shock and hydrocortisone may provide their blood pressure correcting effect by reducing AT2 level in these patients. AT2 can be a therapeutic target in the catecholamine-resistant septic shock patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|